Intranasal vax shows superior protection in animals: Biotech | India News


HYDERABAD: Even as Bharat Biotech has applied to the Indian drug regulator for permission to conduct Phase-I/II trials of its intranasal Covid-19 candidate code named BBV154, the company said the candidate has already shown superior protection against SARS-CoV-2 in animal studies.
BBV154 is a single-dose vaccine made using novel chimpanzee adenovirus. “Mice and hamsters immunized with a single dose of ChAd-SARS-CoV-2-S conferred superior protection against SARS-CoV-2 challenge, more so than one or two intramuscular immunizations of the same vaccine and dose. Post-challenge with SARS-CoV-2, viral clearance was observed in both lower and upper airways,” the company said on its website.
The pre-clinical testing for toxicology, immunogenicity and challenge studies were conducted in US and India. The results of the study have also been uploaded on biorxiv, a server that carries preprints of research work before it is peer reviewed.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *